Navigation Links
Cardium Launches New AWARE Clinical Study Website
Date:6/11/2008

with diabetes.

About Generx

Generx(TM) (alferminogene tadenovec, Ad5FGF-4) is the lead product candidate in a new class of cardiovascular biologics that is being developed to leverage the body's natural healing processes in response to repeated ischemic stress (insufficient blood flow and myocardial oxygen supply due to coronary heart disease). The natural biologic response to repeated transient ischemia is angiogenesis, the growth of new collateral blood vessels, which is orchestrated by a complex and incompletely understood cascade involving many growth factors. These newly-formed vessels can effectively augment blood flow and oxygen delivery to parts of the patient's heart downstream from a blockage in a coronary artery. In many patients however, including those with recurrent angina, coronary collateral vessel formation is insufficient to meet the heart's needs during stress. Currently available anti-anginal drugs, which may provide symptomatic relief, are generally designed to alter the oxygen demand of the heart muscle or dilate vessels to temporarily relieve angina. Generx is designed to be a disease-modifying angiogenic therapeutic to promote the heart's natural response to ischemia through the growth of new blood vessels to increase blood flow within the heart muscle.

Cardium's therapeutic approach to the treatment of myocardial ischemia associated with coronary heart disease has been the focus of the most widely-conducted clinical studies for Angiogenic Gene Therapy (AGENT-1 through AGENT-4), which involved 663 patients at more than 100 U.S., European and other international medical centers. Generx represents the first and only DNA-based cardiovascular therapeutic to be advanced to Phase 3, and the Company believes it to be the only current Phase 3 product candidate for the potential treatment of patients with stable angina, a chronic medical condition affecting millions of patients in the U.S. and worldwide.

About Cardium

<
'/>"/>
SOURCE Cardium Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Cardium Announces $5.3 Million Registered Direct Offering
2. Cardium Completes $5.3 Million Registered Direct Offering
3. Cardiums Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion
4. Cardiums InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems
5. Cardium Reports on Science Channel Series Featuring InnerCools Endovascular Cooling During Brain Surgery at Stanford University
6. Richard A. Schatz, M.D. Joins Cardiums Scientific Advisory Board
7. Cardium Reports on First Quarter 2008 Highlights and Financial Results
8. Cardium Therapeutics Announces Annual Meeting of Stockholders to be Held June 5, 2008
9. Over and Under(R) Pericardium Covered Stent is now in use in England and Proves Great Deliverability
10. Research Triangle Area Health Care Collaborative Launches Bridges to Excellence(R) Initiative to Improve Quality and Lower Costs
11. Novozymes Launches Enzyme to Reduce Acrylamide in Food
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 29, 2014 July 29, 2014 ... in the biotechnology industry, announced that it has ... Inc. to explore financing opportunities that build shareholder ... breakthrough vaccine platform with the potential to transform ... exclusively licensed the well-established LAMP platform from Johns ...
(Date:7/29/2014)...  Sigma-Aldrich Corporation (NASDAQ: SIAL ) dramatically ... investment in Green Chemistry and donated more than 8,000 ... the Company announced Monday in its new 2013 ... The report comes in a year ... responsible corporate citizen, including recognition for the second consecutive ...
(Date:7/29/2014)... -- United Therapeutics Corporation (NASDAQ: UTHR ... the second quarter ended June 30, 2014. ... medicines are reaching increasing numbers of patients ... Martine Rothblatt, Ph.D., United Therapeutics, Chairman and ... quarter of our extended-release tablet called Orenitram ...
(Date:7/29/2014)... 29, 2014 Eppendorf Centrifuge 5427 ... selection. Eppendorf 5427 R is geared towards high-end applications ... it is targeted towards work requiring high sample throughput. ... as it compliments their extensive 16, 48, and 64 ... microcentrifuge tubes, PCR tubes, PCR strip tubes, and more. ...
Breaking Biology Technology:Immunomic Therapeutics Engages Newport Coast Securities, Inc. 2Immunomic Therapeutics Engages Newport Coast Securities, Inc. 3Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 2Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 11United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 12United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 13International Pipette Distributor, Pipette.com Announces the Addition of the Eppendorf Centrifuge 5427 R to Their Product Portfolio 2
... 24 The Charlotte-Mecklenburg region,certainly has not been immune ... NC Free Clinic Association has seen their highest,demand for ... creator of,Charlotte,s premier health & wellness event, the Charlotte ... , "We can all have ...
... Extensive Experience In Molecular DiagnosticsSALT LAKE CITY, Feb. ... spine care through the development of molecular diagnostic ... has joined the executive management team as the ... Dr. Macina will report directly to Kenneth Ward, ...
... Ore. Researchers have identified the gene that ultimately ... that could some day lead to the repair of ... restoration or even the production of replacement teeth. , ... was already known to have several functions - in ...
Cached Biology Technology:Charlotte Anti-Aging Expo & Symposium Supports Free Clinics 2Axial Biotech Appoints Dr. Roberto Macina to Vice President of Research and Development 2Genetic discovery could lead to advances in dental treatment 2
(Date:7/29/2014)... new book that brings together two of the major ... profile of insect fossils through stunning photographs and unique ... James E Jepson, details the incredible preservation and diversity ... scene for what these remarkable fossils can tell us ... future of our planet. Like the mosquito in Jurassic ...
(Date:7/29/2014)... Many different types of cell, including sperm, bacteria ... as flagella. These protrusions, about one-hundredth of a ... move through fluid. Similar, shorter structures called cilia ... where they perform roles such as moving liquids ... are remarkably versatile: they transport mucus and expel ...
(Date:7/28/2014)... About 100 drugs already approved by the U.S. Food ... prevent the growth of certain bacterial pathogens inside human ... Mediterranean spotted fever. The findings, published in mBio ... for Microbiology, demonstrate a new way of identifying non-antibiotic ... , A handful of drugs on the list ...
Breaking Biology News(10 mins):Unique images bring fossil insects back to life 2Microscopic rowing -- without a cox 2Microscopic rowing -- without a cox 3New route to identify drugs that can fight bacterial infections 2
... as many infant deaths than previously estimated, according to a ... Control and Prevention. , The analysis, published today in Pediatrics, ... 37 completed weeks gestation, contributed to more than one-third of ... "We have long known that babies born too soon face ...
... store iron, a valuable discovery for scientists working to improve ... worldwide problem of iron deficiency and malnutrition in humans. , ... vascular system of the seed of Arabidopsis, a model plant ... vacuole, a plant cell's central storage site. The researchers also ...
... University of Manchester researchers are recruiting people with backache ... ?in the first ever study to discover if therapeutic ... and his team at the University's Centre for Rehabilitation ... sciatica for less than 12 weeks, are not pregnant ...
Cached Biology News:New study: Preterm birth causes one-third of all infant deaths 2Plant studies reveal how, where seeds store iron 2
adult...
DNA Purification...
Porcine Serum Available Anticoagulants: N-02: Citrate N-04: Heparin (Na) N-06: K2EDTA N-08: Potassium Oxalate N-10: EDTA (Na) N-03: Alsevers N-05: ACD N-07: CPD N-09: K3EDTA N-11...
Recombinant Viral CCI/Fc Chimera, CF...
Biology Products: